$4.42
+0.50 (+12.76%)
Open$4.50
Previous Close$3.92
Day High$4.80
Day Low$4.30
52W High$12.46
52W Low$1.76
Volume—
Avg Volume124.8K
Market Cap187.17M
P/E Ratio—
EPS$-29.10
SectorBiotechnology
Analyst Ratings
Buy
9 analysts
Price Target
-8.8% upside
Current
$4.42
$4.42
Target
$4.03
$4.03
$3.03
$4.03 avg
$5.66
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 21.71M | 21.78M | 21.76M |
| Net Income | 4.38M | 3.81M | 4.44M |
| Profit Margin | 20.2% | 17.5% | 20.4% |
| EBITDA | 6.15M | 6.17M | 6.37M |
| Free Cash Flow | 3.82M | 4.48M | 4.63M |
| Rev Growth | +1.1% | -8.2% | +18.1% |
| Debt/Equity | 0.50 | 0.50 | 0.61 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 37.6 | 30.39B |